CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 146 enrolled
Drug / intervention
Infliximab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00512278
NCT00512278Phase 2Completed
CompareCT.gov

Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection

Nizar Zein·interventional·Posted Aug 7, 2007·Updated Sep 13, 2017

In Brief

A Phase 2 clinical trial evaluating Infliximab and Placebo for Hepatitis C. Completed, enrolled 146 participants across 7 sites.

Detailed Summary

The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C
CountriesUnited States
CollaboratorsCentocor, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2007
Enrollment StartJul 1, 2007
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 18.9 years ago

Interventions

Infliximabdrug

Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46

Placebodrug

Placebo